Publication:
An EGFR/Src-dependent β4 integrin/FAK complex contributes to malignancy of breast cancer

cris.lastimport.scopus2025-05-17T22:22:24Z
cris.virtual.departmentAnatomy and Cell Biologyen_US
cris.virtual.departmentSurgery-NTUHen_US
cris.virtual.departmentSurgeryen_US
cris.virtual.orcid0000-0002-3444-8255en_US
cris.virtualsource.department34b505e4-b6ff-4836-b6b1-10171c342778
cris.virtualsource.department34b505e4-b6ff-4836-b6b1-10171c342778
cris.virtualsource.department34b505e4-b6ff-4836-b6b1-10171c342778
cris.virtualsource.orcid34b505e4-b6ff-4836-b6b1-10171c342778
dc.contributor.authorTai Y.-L.en_US
dc.contributor.authorChu P.-Y.en_US
dc.contributor.authorI-RUE LAIen_US
dc.contributor.authorWang M.-Y.en_US
dc.contributor.authorTseng H.-Y.en_US
dc.contributor.authorGuan J.-L.en_US
dc.contributor.authorLiou J.-Y.en_US
dc.contributor.authorShen T.-L.en_US
dc.creatorTai Y.-L.;Chu P.-Y.;I-Rue Lai;Wang M.-Y.;Tseng H.-Y.;Guan J.-L.;Liou J.-Y.;Shen T.-L.
dc.date.accessioned2020-02-27T07:32:33Z
dc.date.available2020-02-27T07:32:33Z
dc.date.issued2015
dc.description.abstractβ4 integrin and focal adhesion kinase (FAK) are often associated with a poor prognosis in cancer patients, and their signaling events have recently been linked to malignant outcomes. Here, we demonstrate, for the first time, physical and functional interactions between β4 integrin and FAK that influence breast cancer malignancy. An amino-terminal linker within FAK is essential for its binding with the cytodomain of β4 integrin. Moreover, EGFR/Src-signaling triggers the tyrosine phosphorylation of β4 integrin, which, in turn, recruits FAK to β4 integrin and leads to FAK activation and signaling. Upon disruption of the β4 integrin/FAK complex, tumorigenesis and metastasis in triple-negative breast cancer were markedly reduced. Importantly, the concomitant overexpression of β4 integrin and FAK significantly correlates with malignant potential in patients with triple-negative breast cancer. This study describes a pro-metastatic EGFR/Src-dependent β4 integrin/FAK complex that is involved in breast cancer malignancy and is a novel therapeutic target for triple-negative breast cancer. ? 2015 Macmillan Publishers Limited.
dc.identifier.doi10.1038/srep16408
dc.identifier.issn2045-2322
dc.identifier.pmid26549523
dc.identifier.scopus2-s2.0-84946887740
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84946887740&doi=10.1038%2fsrep16408&partnerID=40&md5=0bede5af8df5a2424dd341904f33adfa
dc.identifier.urihttps://scholars.lib.ntu.edu.tw/handle/123456789/465958
dc.publisherNature Publishing Group
dc.relation.ispartofScientific Reports
dc.relation.journalvolume5
dc.relation.pages16408
dc.subject.classification[SDGs]SDG3
dc.subject.otherbeta4 integrin; epidermal growth factor receptor; focal adhesion kinase; multiprotein complex; protein binding; protein kinase p60; animal; biological model; breast tumor; cell transformation; disease model; enzyme activation; female; genetics; human; metabolism; mouse; pathology; phosphorylation; signal transduction; triple negative breast cancer; tumor cell line; xenograft; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Enzyme Activation; Female; Focal Adhesion Protein-Tyrosine Kinases; Heterografts; Humans; Integrin beta4; Mice; Models, Biological; Multiprotein Complexes; Phosphorylation; Protein Binding; Proto-Oncogene Proteins pp60(c-src); Receptor, Epidermal Growth Factor; Signal Transduction; Triple Negative Breast Neoplasms
dc.titleAn EGFR/Src-dependent β4 integrin/FAK complex contributes to malignancy of breast canceren_US
dc.typejournal articleen
dspace.entity.typePublication

Files